Sandbox Reserved 1779

Introduction

Figure 1. TSHR with TSH bound. The extracellular and transmembrane domains of the GPCR are shown in green, the hinge region in cyan, the P10 peptide in pink, and thyrotropin bound in pink and yellow.

Thyroid hormones exercise essential functions related to thymocyte activity as well as metabolic processes and oxygen consumption. Misregulation of thyroid hormones causes many disorders related to hypo- or hyperthyroidism. Thus, understanding the signaling of synthesis and release of these hormones is essential to developing therapeutic drugs to combat specific thyroid hormone disorders^[1]. The initiation of synthesis and release of these hormones is caused by the glycoprotein, thyroid stimulating hormone, commonly referred to as TSH or thyrotropin. The thyrotropin receptor is a G-protein coupled receptor that binds TSH and transduces signal to initiate synthesis and release of thyroid hormones. It is important to note that autoantibodies may also bind to this receptor causing inhibition or activation of its desired function. (Figure 1)^[2][3].

Grave's Disease

Grave’s disease is an autoimmune disease that is a result of hyperthyroidism. Hyperthyroidism indicates that the body is producing too much TSH. The binding of to results in the receptor remaining in its active conformation. This is important as the thyroid gland controls metabolism in the body and overstimulation can lead to many side effects. This is including but not limited to: eye and skin problems, weight loss, fatigue, muscle weakness, trouble tolerating heat/ profuse sweating, enlarged thyroid glands (goiter). This disease effects 1 in 100 Americans and especially women or people older than 30 years of age. Grave's Disease

Hypothyroidism

Hypothyroidism is the converse of Grave’s Disease as there is not enough TSH produced in the body with this disease. The most common cause of Hypothyroidism is Hashimoto’s disease. Without enough TSH to bind TSHR, the pathway remains inactive and thus metabolic processes are inhibited in this pathway. This results in many symptoms including, but not limited to fatigue, cold sensitivity, weight gain, irregular/heavy menstrual cycle, thinning of hair, and depression. This disease effects women and those older than the age of 60, but can also occur in infancy. Hypothyroidism

Structure

Overview

The thyrotropin receptor has an extracellular domain (ECD) that is composed of a as well as a hinge region. This links the ECD to the seven transmembrane helices , which span from the extracellular domain to the intracellular domain ^[4]. When thyrotropin or an autoantibody binds, it causes a conformational change in the receptor through the transmembrane helices. This causes the thyrotropin receptor to interact differently with its respective when in active and inactive states.

Leucine Rich Region

The Leucine Rich region (LRRD) is part of the of TSHR. The highlighted region contains within the structure. The specific residues from TSHR interacting with TSH are K209 and K58 ^[2]. These interact with in the seatbelt region of TSH forming a salt bridge and initiating the conformational change in the receptor ^[5]. This interaction is specific to TSH and TSHR. When other agonists or antagonists bind to the receptor, the change in conformation is a result of different residues interacting. The Leucine residues likely play a role in how the ECD folds and which residues are located on the exterior protein. As Leucine is hydrophobic, it would be forced into the interior of the protein during folding exposing other residues that are more hydrophilic and likely to interact externally.

Hinge Region and P10 Peptide

Several parts of TSHR are very important for the functioning of TSH signaling. The is a scaffold for the attachment of the ECD to the 7TMD. This region has also been found to have impact on the binding potency of TSH as well as intracellular cyclic adenosine monophosphate (cAMP) levels, which are partially mediated by the activation of the GPCR. Several features of this region have been found to be crucial to the activation of the TSHR by TSH.^[6]. The most important feature of the hinge region is the interaction of the with the through disulfides. The p10 peptide is a conserved sequence that spans from the last beta sheet of the LRRD to the first transmembrane helix (TM1)^[7]. These disulfides are critical because they link the ECD (where thyrotropin binds) to the TMD, whose conformational changes directly activate the receptor's complementary G-protein. The movement of the ECD, which is caused by TSH binding, will cause rotation of the hinge helix and movement of the p10 peptide. This leads to movement of the transmembrane helices which cause activation of the G-protein. In addition to activation, the hinge region plays an important role in tightly binding TSH. Residues 382-390 of the hinge region adopt a short helix containing Y385 and D386. Y385 is buried into a hydrophobic region of TSH while D386 forms a salt bride with R386 of the hormone. Together, facilitate the stable binding of TSH to the TSHR ^[2]. Additionally, it is important to acknowledge the hinge region itself is not required for the activation of the receptor. In many of the aforementioned misregulations of thyroid hormone release, auto-antibodies are responsible. These auto-antibodies bind to the receptor through alternative interactions which cause conformational changes to the 7TMD without any need for a conformational change or extensive interactions with the hinge region^[7].

7 Transmembrane Helices

The thyrotropin receptor is anchored to the membrane through seven transmembrane helices which is characteristic of GPCRs. Conformational changes in this region of the receptor are responsible for the activation of associated G protein^[4]. In thyrotropin binding, changes to this region are mediated by movements in the p10 peptide. When the hinge helix rotates, it causes p10 peptide displacement that allows the of the transmembrane domain to migrate towards the center of the 7TMD to increase Van der Waals contacts. In addition, K660 of TM7 forms an with glutamate 409 of the p10 region. This interaction assists in the stabilization of the active state of 7TMD. In addition, the movement of the hinge helix has been found to bee associated with movement of a tyrosine residue relative to and isoleucine residue on the neighboring extracellular loop 1 (ECL1) helix. The identity of these residues has been found to be an important predictor in the activation of the thyrotropin receptor. For instance, structurally guided mutagenic studies have shown that the mutation of the isoleucine to a more sizeable phenylalanine decreases TSH signaling potency^[7][8].In addition to these conformational changes, the sixth transmembrane helix of TSHR is also moved outward from the center of the 7TMD to facilitate alpha helix 5 of the alpha subunit of the G protein, which is the domain that becomes activated^[7][9].

Active and Inactive Form

Figure 2: Inactive form of the thyrotropin receptor shown in blue. Active form of the thyrotropin receptor shown in green.

The TSHR protein exists in two states: active and inactive (Figure 2). The protrudes from the cell membrane into the space outside the cell. The contains 7 alpha helices that reside within the cell membrane. The exists when bound to the . One proposed mechanism for the transition from the active to inactive describes that in a natural state, the TSHR ECD can spontaneously transition to the up state, leading to constitutive activity. In this active state, TSH will bind and keep the active state in the up position because of clash with the cell membrane.^[5] Conformational change of ECD allows for signal transduction through the TM and into the cell. The ECD rotates 55 degrees up in the active form. ^[5]

TSHR Agonists and Antagonists

Chemical agonists are found in many living systems and serve as a way to activate receptors or pathways that are necessary for a wide array of biological processes. Chemical antagonists block or inhibit biological processes. Different types of agonists/antagonists exist within the body including hormones, antibodies, and neurotransmitters. The body naturally produces autoantibodies that can act as agonists and mimic the activating mechanism of the natural hormone. Isolating these antibodies in patients with diseases can lead researchers to uncover the mechanism of binding for the receptor.

M22 Agonist

Figure 3: Agonist and antagonist drugs for activating or inactivating the TSHR protein.

CS-17 Inverse Agonist

is a monoclonal antibody that acts as an inverse agonist for TSHR constitutive activity. ^[11]. CS-17 interacts with the ECD of the TSHR protein on the convex side of the LRRD. When bound to TSHR, CS-17 suppresses TSHR function by keeping the receptor in the inactive state (Figure 3). Clash with the cell membrane does not allow the inactive form of TSHR to flip to the active conformation. CS-17 plays a unique role with GPCRs. This type of inhibition is not commonly seen in many biological systems and therefore leads to this method of inhibition being a great target for drug design and future research.^[11]. Due to its unique inhibition, CS-17 can be a popular therapy for many thyroid diseases where the thyroid is overactive.

TSH Agonist

Figure 4

Thyroid-stimulating hormone , as previously mentioned, is a hormone that stimulates the thyroid gland to produce proteins that are vital for many metabolic pathways in the body's tissue. TSH activates the TSHR protein by binding to the concave surface of the LRRD and hinge region to keep TSHR in its active state by clashing with the membrane ^[12]. (Figure 3). This clash is caused by glycosylations of an N52 residue on the . These modifications to the N residue are N-acetyl glucosamine modifications (Figure 4). They stick out from the alpha subunit of TSH to clash with the cell membrane and keep TSH in the active state.